Maybe this is the link you're talking about[?]. It addresses the effectiveness of Evenity following Prolia as well as that of alendronate, risedronate, and zoledronic acid.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081316/
Here's a snippet:
"When administered after denosumab in postmenopausal women with low BMD, romosozumab increased BMD in the lumbar spine by 2.3% and maintained BMD in the hip, although the increase was of a smaller magnitude than that observed in treatment-naïve patients."